AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Vaxart, Inc.
Video analysis: VXRT
All videosNo video analysis for this stock yet. Request one from our team.
News: VXRT
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that a member of its management team will present at the H.C.
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European markets European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European markets
Vaxart Q2 Earnings Call Highlights
Vaxart OTCMKTS: VXRT said it has reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial and remains on track to disclose top-line data from the larger, approximately 5,000-participant main cohort in the first half of 2027.
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
Company to report second quarter 2026 financial results on August 6 SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the Company's senior management team will participate in a virtual fireside chat on Friday, August 7, 2026, at 4:30 p.m.
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
Vaxart (OTCMKTS:VXRT) held its 2026 Annual Meeting of Stockholders, where investors re-elected the company's full slate of directors, ratified its auditor and rejected the company's non-binding advisory proposal on executive compensation. Mark Watson, Vaxart's lead independent director and chair of the meeting, said proxies had been received for 110,631,100 of the company's 242,044,838 outstanding shares
Vaxart to Participate in BTIG Biotechnology Conference 2026
SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026.
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
Vaxart OTCMKTS: VXRT held its 2026 Annual Meeting of Stockholders, where investors re-elected the company's full slate of directors, ratified its auditor and rejected the company's non-binding advisory proposal on executive compensation.
